Nafdac Refuses to Discontinue Hydroxychloroquine Trials for Coronavirus Patients Despite Who's stoppage Orders

The National Agency for Food and Drug Control (NAFDAC) has said Nigeria will continue with hydroxychloroquine trials for the coronavirus patients. This statement came at the time when the World Health Organisation (WHO) ordered the trial to be stopped throughout the globe.

In a statement released by NAFDAC's DG, Mrs Mojisola Adeyeye on Tuesday, she said that the drug has proven to be effective at the early stage of the coronavirus infection.

In her statement, "There is data to prove that hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria.
Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body.”

Post a comment

0 Comments